Research Institute: Monash Institute of Medical Research
Amount granted: $1.6 million
Year granted: 2010
This grant enabled the Monash Health Translation Precinct to establish the ACRF Centre for Cancer Genomic Medicine (ACCGM).
The Centre allows the genetic profiling of specific cancers. This information is critical to the development and application of anticancer drugs tailored to individual patients.
By purchasing the latest in DNA sequencing technologies, called second and third generation platforms, the ACCGM has been able to introduce molecular-based based patient tumour profiles for everyday cancer patient management.
The establishment of the ACCGM allowed a greater insight into the nature of the genes involved in cancer. This has been invaluable not only for cancer prognosis, but also for identifying patients that may or may not respond to new therapies.
Chief Investigators: Prof Bryan Williams, Prof Paul Hertzog, Prof Neil Watkins, Associate Prof Brendan Jenkins, Prof Gail Risbridger, Prof Matthew Gillespie, Prof Evan Simpson, Prof Peter Fuller
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.